Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study
Amgen(US:AMGN) Yahoo Finance·2025-10-16 05:59Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study Photo by Annie Spratt on Unsplash Amgen Inc. (NASDAQ:AMGN) is a California-based biopharmaceutical company. On October 3, Oppenheimer reaffirmed its Outperform rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $380. The firm highlighted Amgen’s solid performance and also reported that ...